More Galleries
5 startups that are reimagining the world Bricks that grow from microorganisms, household garbage turned into art, three-wheeled bike-cars -- these startups are redefining urban living. More
Blue collar entrepreneurs These five entrepreneurs took their blue collar experience and used it to launch innovative businesses. More
7 lifehacks to eliminate your holiday hassle Whether curating the perfect gift or finding a pet-sitter, these startups offer time-saving services that might just seem like holiday magic. More

Special Offer
9 of 36
BACK NEXT
A nanotherapy for liver cancer
A nanotherapy for liver cancer
Jordi de los Pinos, Elisabet de los Pinos and Zeid Barakat
Team name: Aura Biosciences

School name: MIT, Sloan School of Management

Team members: Elisabet de los Pinos, Jordi de los Pinos, Zeid Barakat

Concept: Patents on many drugs used to treat liver cancer (which kills 650,000 people each year) will expire within the next five years. Aura Biosciences aims to give pharmaceutical companies such as Sanofi-Aventis and Eli Lilly a chance to extend those patents by licensing the use of tiny "nanosmart" particles, only 20 nanometers wide, that deliver the drugs directly to tumor cells, reducing patient side effects while increasing efficacy and survival rates.

The company also plans to push for an "orphan drug" designation from the the U.S. Food & Drug Administration and the European Medicines Agency that may reduce required trial times, increase government support for development and marketing, and grant short-term market exclusivity. The technology is highly experimental: Much of Aura's funding will cover trials necessary to gain regulatory approval and convince skeptical drug manufacturers. But Phase III licensing agreements are frequently highly lucrative, with the potential for extensive royalties as well as up-front payments in the tens or hundreds of millions.

Timeline: The team plans to start Phase I European trials in 2009 and Phase II trials in the U.S. in 2010, with the goal of licensing its technology to a major pharmaceutical manufacturer by 2012. - Rose Fox

NEXT: Easier TB diagnosis

Last updated May 02 2008: 11:51 AM ET

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.